Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fred C. Lam has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Radiomodulation—The Final Frontier of Radiosurgery?

    by Fred C. Lam, Evan Chau, Yazhen Shi, Bryan Martinez, Amar Hamdan, Jay L. Gill, Nirmeen Zagzoog, Neeraj Kalra, Yusuke S. Hori, Michael B. Schneider, et al.

    Stereotactic radiosurgery (SRS) delivers high doses of focused ionizing radiation (IR) to a defined target while sparing surrounding tissues. The delivery of focused doses of IR has proven to be an effective modality for the treatment of brain tumors, cerebrovascular lesions, and primary neuropathic pain conditions. More recently, the emerging concept of “radiomodulation” to rewire neural circuitry through the delivery of focused IR to specific neural relay centers has emerged as an alternative way to treat neurological conditions, such as essential tremor, trigeminal neuralgia, and psychiatric illnesses. In this article, we performed a scoping review of the existing data supporting the ability of focused doses of ionizing radiation to achieve modulation of neural circuits for the treatment of neurological conditions. We review the current understanding of the neurophysiological mechanisms of radiomodulation, the gaps in knowledge limiting its widespread use for in-human applications and stress the unmet need for ongoing research to rigorously prove that radiomodulation may be the “final frontier” as a non-invasive, non-pharmacological, versatile, and tunable modality for the treatment of a multitude of neurological conditions.

  • Open Access

    Hepatoblastoma brain metastasis treated with stereotactic radiosurgery: Illustrative case and literature search

    by Muhammad Izhar, Ahed H. Kattaa, Yusuke S. Hori, Fred C. Lam, Armine Tayag, Louisa Ustrzynski, Sara C. Emrich, Iris C. Gibbs, David J. Park, Steven D. Chang

    Background: Hepatoblastoma (HB) is the most prevalent pediatric liver malignancy, typically affecting children under 5 years of age. Although advances in multimodal therapy, including surgical resection and chemotherapy, have significantly improved survival rates, distant metastases, particularly to the lungs and the brain, remain a critical prognostic challenge. Brain metastases (BMs) from HB are exceedingly rare, with only a limited number of cases reported in the literature, and the management of these lesions is challenging. Stereotactic radiosurgery (SRS) is an increasingly popular treatment option for BM due to its ability to deliver high doses of radiation to the target volume with minimal exposure to surrounding normal tissues. In this paper, we present a rare case of HB with brain metastasis that was treated with SRS for the 1 st time. Case Description: The case was a 4-year-old male with a history of stage IV HB who was diagnosed with a single BM. Post-treatment magnetic resonance images following SRS revealed a reduction in lesion size on 6 th -month follow-up imaging and then a stable lesion on further follow-up imaging. The case highlights the potential efficacy of SRS as a treatment option for BM from HB and supports its usage in the management of this complex condition. The progression-free survival was 17 months, and the overall survival was 84 months. Conclusion: SRS may represent a safe and effective treatment modality for HB BM, particularly in patients who are not suitable candidates for surgical resection or systemic therapy. Larger studies with extended follow-up are necessary to more accurately assess the long-term safety, efficacy, and clinical utility of SRS in the management of HB-related BM.


  • Open Access

    Characterizing the Microenvironment of Cerebral Arteriovenous Malformations to Test Novel Treatment Modalities

    by Kavin Wazhi, Fred C. Lam, Santosh Guru, Yusuke S. Hori, Deyaldeen AbuReesh, Lorelei Shoemaker, David J. Park, Steven D. Chang

    Brain arteriovenous malformations (bAVMs) consist of a tangled nidus of abnormal dilated vessels characterized by direct connections between arteries and veins that lack an intervening capillary bed, creating a high-to-low flow pressure system that is predisposed to spontaneous hemorrhage with significant associated neurologic morbidity and mortality. Treatment options for bAVMs include the following: surgical resection, intravascular embolization to obliterate blood flow through the AVM, and radiosurgery. Understanding the molecular mechanisms of bAVM formation and factors that predispose it to hemorrhage can lead to novel treatments that can improve the prognosis for patients. This review summarizes emerging insights into the complex and dynamic molecular mechanisms of bAVMs. Dysregulation in key VEGF, TGF-β/BMP9/10–ENG–ALK1–SMAD4, Notch, and MAPK/ERK signaling pathways drive abnormal angiogenesis in both syndromic and sporadic forms, with KRAS/BRAF/MAPK21 mutations specifically linked to the latter. Advances in bAVM-induced animal models have corroborated many of the genetic profiles found in humans, and they continue to provide novel insights into bAVM mechanisms. Collectively, these mechanistic findings are guiding translational advances, with targeted therapies and liquid biopsy approaches emerging as avenues for precision treatment and improved patient outcomes.


  • Open Access

    Current State-of-the-Art Animal Models of Pediatric Brain Tumors

    by Tanusri Gudavalli, Fred C. Lam, Santosh Guru, Deyaldeen AbuReesh, Yusuke S. Hori, Susan Hiniker, David J. Park, Steven D. Chang

    Brain tumors are unfortunately the most common types of solid tumors in the pediatric population, superseded only by leukemias, and largely bode a poor prognosis. Despite advances in our ability to diagnose and treat pediatric brain tumors, there remains a large unmet need to develop novel therapies to improve patient outcomes. The recent understanding of the molecular drivers of oncogenesis for many of these tumors has led to the engineering of preclinical small animal models which serve as valuable tools for scientists to study the mechanisms of tumor biology, to understand interactions with the tumor microenvironment, and allow for translatable novel therapeutic discovery. This review focuses on the state-of-the art development of preclinical models of two difficult-to-treat pediatric brain tumors: (1) diffuse midline gliomas, the most lethal form of pediatric brain cancer; (2) medulloblastoma, the most common embryonal tumor of the central nervous system. We will then round off this review with a discussion on the emerging use of multi-omics and AI approaches to complement the testing of novel therapies using these in vivo animal models.


  • Open Access

    Efficacy and Safety of CyberKnife Stereotactic Radiosurgery for Occipital Condyle Metastasis

    by David J. Park, Harini Voruganti, Shreyas Annagiri, Elaheh Shaghaghian, Yusuke S. Hori, Amit R. Persad, Kelly H. Yoo, Deyaaldeen Abu-Reesh, Fred C. Lam, Armine Tayag, et al.

    BACKGROUND AND OBJECTIVES: Occipital condyle metastasis (OCM) is a rare condition characterized by severe occipital pain and neurological symptoms due to lower cranial nerve (CN) deficits, stemming from its anatomic location. Despite the widespread use of stereotactic radiosurgery (SRS) for cranial metastases, its specific impact on OCM remains underexplored. This study evaluates the efficacy and safety of CyberKnife SRS in treating OCM, focusing on occipital pain, dysfunctions of lower CNs, and local tumor control. METHODS: We retrospectively analyzed cases of OCM treated with SRS at our institute from 2012 to 2023, evaluating patient demographics, presenting symptoms, treatment parameters, and outcomes. RESULTS: Eighteen patients (10 females) with a mean age of 64 years (SD: 10.4) were treated. Common presentations included occipital pain (44.4%) and lower CN deficits (27.8%). The median target volume was 6.95 cc (IQR: 4.64-21.2). The mean single-fraction equivalent dose was 18.7 Gy10 (SD: 1.9). Ten tumors received 15-20 Gy in 1 fraction (50%), 2 tumors received 20-28 Gy in 2 fractions (10%), 4 tumors received 27 Gy in 3 fractions (20%), and 4 tumors received 30-40 Gy in 5 fractions (20%). Based on Kaplan-Meier estimate, SRS achieved 93.8% local tumor control rate over 3 years, with a median overall survival of 13 months (95% CI: 0-32.2). Among patients presenting with symptoms, 87.5% reported occipital pain relief (P = .04), and 80% observed improvements in CN function (P = .003). Four patients experienced local recurrence. CONCLUSION: CyberKnife SRS is a promising treatment of OCM, offering significant pain relief and improvement in neurological symptoms, along with favorable local control rates. This noninvasive therapy provides a valuable alternative to surgery, potentially enhancing the quality of life for patients with limited treatment options due to this challenging condition.


  • Open Access

    Stereotactic radiosurgery for brain metastases from non-uterine Leiomyosarcoma: A retrospective case series

    by Juan J. Cardona, Yusuke S. Hori, Ahed H. Kattaa, Paul M. Harary, Fred C. Lam, Deya Abu-Reesh, Louisa Ustrzynski, Sara C. Emrich, Armine Tayag, Melanie Hayden-Gephart, et al.


  • Open Access

    Stereotactic Radiosurgery for Recurrent Meningioma: A Systematic Review of Risk Factors and Management Approaches

    by Yuka Mizutani, Yusuke S. Hori, Paul M. Harary, Fred C. Lam, Deyaaldeen Abu Reesh, Sara C. Emrich, Louisa Ustrzynski, Armine Tayag, David J. Park, Steven D. Chang

    Background/Objectives: Recurrent meningiomas remain difficult to manage due to the absence of effective systemic therapies and comparatively high treatment failure rates, particularly in high-grade tumors. Stereotactic radiosurgery (SRS) offers a minimally-invasive and precise option, particularly for tumors in surgically complex locations. However, the risks associated with re-irradiation, and recent changes in the WHO classification of CNS tumors highlight the need for more personalized and strategic treatment approaches. This systematic review evaluates the safety, efficacy, and clinical considerations for use of SRS for recurrent meningiomas. Methods: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic literature search was conducted using the PubMed, Scopus, and Web of Science databases for studies reporting outcomes of SRS in recurrent, pathologically confirmed intracranial meningiomas. Studies were excluded if they were commentaries, reviews, case reports with fewer than three cases, or had inaccessible full text. The quality and risk of bias of the included studies were assessed using the modified Newcastle-Ottawa Scale. Data on patient and tumor characteristics, SRS treatment parameters, clinical outcomes, adverse effects, and statistical analysis results were extracted. Results: Sixteen studies were included. For WHO Grade I tumors, 3- to 5-year progression-free survival (PFS) ranged from 85% to 100%. Grade II meningiomas demonstrated more variable outcomes, with 3-year PFS ranging from 23% to 100%. Grade III tumors had consistently poorer outcomes, with reported 1-year and 2-year PFS rates as low as 0% and 46%, respectively. SRS performed after surgery alone was associated with superior outcomes, with local control rates of 79% to 100% and 5-year PFS ranging from 40.4% to 91%. In contrast, tumors previously treated with radiotherapy, with or without surgery, showed substantially poorer outcomes, with 3- to 5-year PFS ranging from 26% to 41% and local control rates as low as 31%. Among patients with prior radiotherapy, outcomes were particularly poor in Grade II and III recurrent tumors. Toxicity rates ranged from 3.7% to 37%, and were generally higher for patients with prior radiation. Predictors of worse PFS included prior radiation, older age, and Grade III histology. Conclusions: SRS may represent a reasonable salvage option for carefully selected patients with recurrent meningioma, particularly following surgery alone. Outcomes were notably worse in high-grade recurrent meningiomas following prior radiotherapy, emphasizing the prognostic significance of both histological grade and treatment history. Notably, the lack of molecular and genetic data in most existing studies represents a key limitation in the current literature. Future prospective studies incorporating molecular profiling may improve risk stratification and support more personalized treatment strategies.


  • Open Access

    Overview of Preclinical and Clinical Trials of Nanoparticles for the Treatment of Brain Metastases

    by Muhammad Izhar, Mohamed Al Gharyani, Ahed H. Kattaa, Juan J. Cardona, Ruchit P. Jain, Elaheh Shaghaghian, Yusuke S. Hori, Fred C. Lam, Deyaaldeen Abu Reesh, Sara C. Emrich, et al.

    Brain metastases (BM), which most commonly originate from lung, breast, or skin cancers, remain a major clinical challenge, with standard treatments such as stereotactic radiosurgery (SRS), surgical resection, and whole-brain radiation therapy (WBRT). The prognosis for patients with BM remains poor, with a median overall survival (OS) of just 10–16 months. Although recent advances in systemic therapies, including small molecule inhibitors, monoclonal antibodies, chemotherapeutics, and gene therapies, have demonstrated success in other malignancies, their effectiveness in central nervous system (CNS) cancers is significantly limited by poor blood–brain barrier (BBB) permeability and subtherapeutic drug concentrations in the brain. Nanoparticle-based drug delivery systems have emerged as a promising strategy to overcome these limitations by enhancing CNS drug penetration and selectively targeting metastatic brain tumor cells while minimizing off-target effects. This review summarizes recent preclinical and clinical developments in nanoparticle-based therapies for BM. It is evident from these studies that NPs can carry with them a range of therapeutics, including chemotherapy, immunotherapy, small molecule inhibitors, gene therapies, radiosensitizers, and modulators of tumor microenvironment to the BM. Moreover, preclinical studies have shown encouraging efficacy in murine models, highlighting the potential of these platforms to improve therapeutic outcomes. However, clinical translation remains limited, with few ongoing trials. To close this translational gap, future work must address clinical challenges such as trial design, regulatory hurdles, and variability in BBB permeability while developing personalized nanoparticle-based therapies tailored to individual tumor characteristics.


  • Open Access

    A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis

    by Shawn C. Chafe, Kui Zhai, Nikoo Aghaei, Petar Miletic, Zhi Huang, Kevin R. Brown, Daniel Mobilio, Daniel Young, Yujin Suk, Shan Grewal, et al.

    Brain metastasis occurs in up to 40% of patients with non–small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer’s disease–associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis.


  • Open Access

    Radiosensitizers in Cancer Therapy: A Global Bibliometric Analysis

    by Shreyas Annagiri, Paul M. Harary, Yusuke S. Hori, Fred C. Lam, Deyaldeen AbuReesh, Armine Tayag, Lousia Ustrzynski, Sara C. Emrich, Steven D. Chang, David J. Park

    Background/Objectives Radiosensitizers are compounds given concurrently with radiotherapy to enhance the killing of cancer cells while sparing healthy tissue. Radiosensitization research has involved a diverse range of therapeutic agents. In the present study, we aimed to investigate international trends in the development of radiosensitizers across the most common cancer types. Methods A bibliometric analysis was performed of the field of radiosensitizer research from 1956 to 2024. Individual author impacts and trends, collaborations between and productivity of countries, and themes/keywords were analyzed. Results Our search yielded 12,690 results. The most highly represented countries were the United States of America, China, and Germany. Radiosensitizer studies for breast cancers demonstrated the highest rate of annual growth in record count by comparison with other cancer types, while publications for gynecological cancers showed the slowest growth. The most common radiosensitizers investigated included ATM kinase inhibitors, chemotherapies, gold nanoparticles, mTOR inhibitors, natural compounds such as caffeine or curcumin, and poly (ADP-ribose) polymerase inhibitors. Conclusions The United States, Germany, and China were the most productive countries during the study period, with China demonstrating the greatest increase in annual publication rate. Additionally, pre-clinical studies primarily investigated gold particles and targeted therapies. By comparison, clinical studies focused on radiosensitizing chemotherapies.